Patents by Inventor Kazunobu Kira

Kazunobu Kira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210261566
    Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.
    Type: Application
    Filed: February 4, 2021
    Publication date: August 26, 2021
    Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Publication number: 20210163456
    Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
    Type: Application
    Filed: April 8, 2019
    Publication date: June 3, 2021
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Gregg F. KEANEY, John WANG, Baudouin GERARD, Kenzo ARAI, Xiang LIU, Guo Zhu ZHENG, Kazunobu KIRA, Lisa A. MARCAURELLE, Marta NEVALAINEN, Ming-Hong HAO, Morgan Welzel O'SHEA, Parcharee TIVITMAHAISOON, Sudeep PRAJAPATI, Touping LUO, Nicholas C. GEARHART, Jason T. LOWE, Yoshihiko KOTAKE, Satoshi NAGAO, Regina Mikie KANADA SONOBE, Masayuki MIYANO, Norio MURAI, Andrew COOK, Shelby ELLERY, Atsushi ENDO, James PALACINO, Dominic REYNOLDS
  • Patent number: 10954249
    Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 23, 2021
    Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., Ltd.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Publication number: 20200361915
    Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 19, 2020
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
  • Publication number: 20200325152
    Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
    Type: Application
    Filed: November 15, 2018
    Publication date: October 15, 2020
    Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Patent number: 10745387
    Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 18, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
  • Publication number: 20200148698
    Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof.
    Type: Application
    Filed: April 3, 2018
    Publication date: May 14, 2020
    Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Publication number: 20190100513
    Abstract: The present disclosure provides a novel solid state form of pladienolide pyridine compounds, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Application
    Filed: November 17, 2016
    Publication date: April 4, 2019
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim, Atsushi Endo, Arani Chanda
  • Patent number: 9938288
    Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: April 10, 2018
    Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Patent number: 9481669
    Abstract: The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: November 1, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Silvia Buonamici, Lihua Yu, Eunice Sun Park, Betty Chan, Peter G. Smith, Michael P. Thomas, Ermira Pazolli, Kian Huat Lim
  • Publication number: 20150329528
    Abstract: The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Application
    Filed: May 13, 2015
    Publication date: November 19, 2015
    Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Parcharee Tivitmahaisoon, Sudeep Prajapati, Nicholas C. Gearhart, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai
  • Publication number: 20140275010
    Abstract: The present invention provides quaternary salts, such as those of Formula I: as well as the use thereof in methods of treatment for cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Inventors: Guo Zhu Zheng, Yuan Wang, Gregg F. Keany, Kenzo Arai, Kazunobu Kira, Xiang Liu, Nick Gearhart, Baudouin Gerard
  • Patent number: 8436009
    Abstract: By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: May 7, 2013
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Richard Clark, Fumiyoshi Matsuura, Masanobu Shinoda, Shinsuke Hirota, Kazunobu Kira, Hiroshi Azuma, Atsushi Takemura, So Yasui, Kazutomi Kusano, Masaki Mikamoto, Takao Omae
  • Publication number: 20130053563
    Abstract: By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation.
    Type: Application
    Filed: May 18, 2011
    Publication date: February 28, 2013
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Richard Clark, Fumiyoshi Matsuura, Masanobu Shinoda, Shinsuke Hirota, Kazunobu Kira, Hiroshi Azuma, Atsushi Takemura, So Yasui, Kazutomi Kusano, Masaki Mikamoto, Takao Omae
  • Patent number: 8163787
    Abstract: A compound represented by the following general formula (1) or salts thereof or hydrates of the foregoing: wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: April 24, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Richard Clark, Fumiyoshi Matsuura, Kazunobu Kira, Shinsuke Hirota, Hiroshi Azuma, Tadashi Nagakura, Tatsuo Horizoe, Kimiyo Tabata, Kazutomi Kusano, Takao Omae, Atsushi Inoue
  • Publication number: 20110112109
    Abstract: A compound represented by the following general formula (1) or salts thereof or hydrates of the foregoing: wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen.
    Type: Application
    Filed: January 13, 2011
    Publication date: May 12, 2011
    Inventors: Richard CLARK, Fumiyoshi Matsuura, Kazunobu Kira, Shinsuke Hirota, Hiroshi Azuma, Tadashi Nagakura, Tatsuo Horizoe, Kimiyo Tabata, Kazutomi Kusano, Takao Omae, Atsushi Inoue
  • Patent number: 7928228
    Abstract: A Compound represented by the following general formula (1): wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen or salts thereof or hydrates of the foregoing.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: April 19, 2011
    Assignees: Eisai Co., Ltd., Eisai R&D Management Co., Ltd.
    Inventors: Richard Clark, Fumiyoshi Matsuura, Kazunobu Kira, Shinsuke Hirota, Hiroshi Azuma, Tadashi Nagakura, Tatsuo Horizoe, Kimiyo Tabata, Kazutomi Kusano, Takao Omae, Atsushi Inoue
  • Patent number: 7816522
    Abstract: A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: October 19, 2010
    Assignee: Eisai Co., Ltd.
    Inventors: Richard Clark, Fumiyoshi Matsuura, Kazunobu Kira, Shinsuke Hirota, Hiroshi Azuma, Tadashi Nagakura, Tatsuo Horizoe, Kimiyo Tabata, Kazutomi Kusano, Takao Omae, Atsushi Inoue
  • Publication number: 20100240654
    Abstract: A compound represented by the following general formula (1) or a salt thereof or a hydrate of the foregoing is safe while exhibiting suitable physicochemical stability, and is useful as therapeutic or prophylactic agents for diseases associated with thrombus formation. wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc., R2 represents optionally substituted phenyl, etc., R3 represents optionally substituted C6-10 aryl, etc., Z1, Z2 and Z3 each independently represent hydrogen, etc., Z4 represents hydrogen, etc. and X represents a single bond or —CO—, etc.
    Type: Application
    Filed: June 1, 2010
    Publication date: September 23, 2010
    Inventors: Richard CLARK, Shinsuke HIROTA, Hiroshi AZUMA, Kazunobu KIRA, Nobuhisa WATANABE, Tadashi NAGAKURA, Tatsuo HORIZOE
  • Patent number: 7772226
    Abstract: The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C1-6 alkyl group which may have one or more substituents, or such; Z1 and Z2 each independently represent a nitrogen atom or a group represented by the formula —CR2—; R1 and R2 independently represent a hydrogen atom, a C1-6 alkyl group which may have one or more substituents, or a C1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: August 10, 2010
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Seiji Yoshikawa, Eita Emori, Fumiyoshi Matsuura, Richard Clark, Hironori Ikuta, Kazunobu Kira, Nobuyuki Yasuda, Tadashi Nagakura, Kazuto Yamazaki